Hims & Hers Review 2026: GLP-1 Weight Loss, Telehealth Prescriptions, and Honest Verdict

Overview: What Is Hims & Hers?

Hims & Hers Health (NYSE: HIMS) is a publicly traded direct-to-consumer telehealth and pharmacy company that started in 2017 with men's hair loss and erectile dysfunction medications and has aggressively expanded into mental health prescriptions, dermatology, sexual health, primary care, and — most consequentially — GLP-1 weight loss drugs. The company runs an integrated stack: AI-driven intake, asynchronous telehealth visits with licensed providers, in-house compounding pharmacies, and direct-to-door subscription delivery.

Hims is the men's brand; Hers is the women's brand; the underlying platform is the same. The company's signature move in 2024-2025 was launching compounded semaglutide at $165/month, undercutting branded Wegovy and Ozempic ($1,200-$1,800/month) by an order of magnitude and generating massive growth — and equally massive regulatory and clinical scrutiny.

Pricing Breakdown

The pricing model is subscription-based and bundled. For most categories, the monthly fee covers the asynchronous provider visit, ongoing prescriber access, the medication itself, and shipping. For mental health (anxiety/depression generics like sertraline or escitalopram) at $85/month, this is competitive with traditional psychiatry copays once you account for visit fees. For compounded GLP-1 at $165/month, this is dramatically cheaper than branded alternatives — but the medication is being produced under the FDA's compounding allowance during the official shortage of branded semaglutide, and that allowance is expected to narrow as supply normalizes.

The GLP-1 Question: Compounded vs Branded

Compounded semaglutide is produced by 503A and 503B compounding pharmacies under federal exemptions that allow compounding of drugs on the FDA shortage list. Wegovy and Ozempic have been on that shortage list since 2022. Hims partners with compounding pharmacies to source semaglutide, packages it in subscription form, and pairs it with provider oversight and lifestyle support.

Three risks deserve serious attention. First, regulatory: when semaglutide leaves the shortage list, the legal basis for mass compounding largely disappears. Hims management has acknowledged this risk in earnings calls. Second, quality: compounded products are not FDA-approved and the source pharmacies vary in standards; the FDA has issued warnings about non-compliant compounders. Third, clinical: the dose, formulation, and inert ingredients of compounded semaglutide are not necessarily identical to branded Wegovy, and outcome data does not transfer cleanly. Hims provides provider oversight, but users should understand that they are taking a non-FDA-approved version of an FDA-approved drug class.

Key Features

• AI-assisted telehealth consultation for prescriptions
• GLP-1 weight loss medication programs (compounded semaglutide)
• Mental health medication prescriptions (anxiety, depression)
• Hair loss and ED treatment subscriptions
• Personalized treatment plans via AI intake
• In-app provider messaging
• Subscription-based medication delivery
• Expanding AI platform for diagnosis-to-delivery integration

The user experience is the strongest part of Hims. Intake is fast (most users complete it in under 10 minutes), provider review and prescription often happen within 24-48 hours, and medication ships discreetly. For categories like hair loss (finasteride, minoxidil) or ED (sildenafil, tadalafil), where the clinical question is well-bounded and the medication is generic, this model is genuinely efficient and removes meaningful friction.

The AI Behind the Platform

Hims uses AI primarily in intake and treatment matching. The questionnaire adapts based on user responses, surfaces appropriate treatment options, and routes the case to the right provider type. Hims management has signaled an "AI-first" platform pivot, with plans for more personalized treatment recommendations and an integrated diagnosis-to-delivery flow. None of the AI involves clinical diagnosis — a licensed provider must approve every prescription — but the routing and documentation layers are increasingly AI-driven.

Pros and Cons

Who Should Use Hims & Hers

Hims & Hers is best for generally healthy adults seeking convenient, well-priced access to generic medications for hair loss, ED, common mental health conditions, dermatology, or sexual health. For these well-bounded, low-risk categories the model works well. For GLP-1 weight loss it can also work, but only for users who understand the regulatory and quality risks of compounded semaglutide and who are willing to accept the trade-off versus paying $1,200+/month for branded alternatives.

Hims & Hers is not appropriate for anyone needing in-person assessment, controlled substances (no Adderall, no benzodiazepines), complex psychiatric care, eating disorders, or care that requires close follow-up. The asynchronous model also makes Hims less suitable for users who want a long-term provider relationship.

Verdict

Hims & Hers is the most efficient pure-play telehealth pharmacy in the US for generic medications and the cheapest legitimate path to compounded GLP-1, but the GLP-1 business carries real regulatory, quality, and clinical risks that buyers should understand. For hair, ED, mental health generics, and dermatology, Hims is a solid recommendation. For weight loss, recommend cautiously and only after reading the fine print on compounding.